Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did anyone make Conf call?
I was traveling..
Recording anywhere?
30.36 > Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease
8:02 am ET October 5, 2021 (Newsfile) Print
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients
Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development
Investor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ET
Berwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor function.
The second part of the study expanded on the original 14 AD and 14 PD patients by recruiting an additional 40 PD patients for a total of 54 PD patients, who were treated with either 0mg, 5mg, 10mg, 20mg, 40mg or 80mg of ANVS401 once daily. Safety and two psychometric assessments - the coding test of the Wechsler Adult Intelligence Scale (WAIS) and the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - were conducted at day 0 and day 25, comparing ANVS401-dosed PD patients with those dosed with placebo. ANVS401 has been found to be well-tolerated and safe with no adverse effects related to treatment observed.
When compared to the placebo group, statistically significant improvements in WAIS coding scores were observed in PD patients taking ANVS401 5mg, 20mg and 80mg once daily, highlighting increased motor-dexterity, as well as speed and accuracy compared to placebo (Figure 1). Further, PD patients taking ANVS401 5mg, 20mg and 80mg also achieved statistically significant improvements from baseline in the same test (Figure 1). PD patients treated with ANVS401 10mg and 20mg once daily showed statistically significant improvements in the UPDRS 2, 3, 4, and in total MDS-UPDRS test compared to baseline (Figure 2).
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7656/98604_abdd38ead4cc6899_002.jpg
Figure 1 - WAIS Coding Test Results for 54 PD Patients - Statistical significance from baseline is signified by an asterisk on the top of a dose bar; statistical significance from placebo is signified by an asterisk on a line from the placebo to a dose bar. Single asterisks represent p<0.05, while two asterisks represent p<0.01.
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7656/98604_abdd38ead4cc6899_002full.jpg
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7656/98604_abdd38ead4cc6899_003.jpg
Figure 2 - MDS-UPDRS Total Results for 54 PD Patients - Patients dosed with 10mg and 20mg showed marked improvement when compared to baseline for motor control and function. Statistical significance from baseline is signified by an asterisk on the bottom of a dose bar. Single asterisks represent p<0.05.
To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/7656/98604_abdd38ead4cc6899_003full.jpg
This dosing study shows that ANVS401 is efficacious across the tested dose range when measured by WAIS coding and shows better efficacy around 10 to 20mg once per day when measured by MDS-UPDRS. This dose range provides guidance as to what doses to use in the upcoming phase 3 studies in AD and PD patients.
"We are thrilled by these improvements in motor function of PD patients. Through examination of this dose-response, we can determine an optimal safe and efficacious dose as we move forward towards initiation of Phase 3 clinical trials with much larger patient populations and longer timelines. These positive efficacy results, which expand on our previous data from AD and PD patients, add clarity to the benefits that ANVS401 may offer to patients suffering from these chronic neurodegenerative diseases," said Founder, President and CEO of Annovis, Maria L. Maccecchini, Ph.D. "We are still analyzing certain biomarker data from the 54 PD patients and will share the results when they are available. We will be asking the FDA for a meeting to receive guidance on next steps in clinical development in light of the AD/PD Phase 2 clinical results."
Annovis Bio will host an investor conference call today, October 5th, 2021, at 9:00 am ET. Interested parties can participate through the following link: https://russopr.zoom.us/j/87423723968
About WAIS and MDS-UPDRS Psychometric Assessments
The WAIS coding subtest measures visual-motor dexterity, associative nonverbal learning, and nonverbal short-term memory. It also measures fine-motor dexterity, speed, accuracy, and ability to manipulate a pencil and perceptual organization.
The MDS-UPDRS evaluates several motor and non-motor experiences specific to the progression of Parkinson's disease, including cognitive impairment, general mental state, facial expression, tremors, and other key features. The UPDRS is the current standard for clinical examination of patients diagnosed with PD.
About Annovis Bio, Inc.
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We have two ongoing Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/ PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD.
For more information on Annovis Bio, please visit the company's website: www.annovisbio.com
Bad guys are bad guys
Shorts got hammered on the way up
Annovis got it’s needed research funds with little dilution..
More clinical
Data THIS year..
Look for steel support
and bury short greed..
New clinical trials can not be far off..
The lesson is always the same. Take chips off the table at different price points. You will never get the absolute top. You shoot for an average exit price.
The way ANVS ran -- you could have been wise and sold 2% positions at different prices and did VERY well. But we all get greedy and think we are stupid for trimming our holdings.
Another lesson learned.
(I did not get out at the top by any means, but I had 80% sold before the dump this week.)
GLTU
$ANVS : WOW...... now $33.33
Whatttttttaaaaaaaaaaaa DUMP
Was just $120 on MONDAY
And thats what its all ABOUT
GO $ANVS
Annovis Bio (ANVS) loses nearly half after presenting Alzheimer's drug data at AAIC 2021
Jul. 29, 2021
By: Mamta Mayani, SA News Editor
Annovis Bio (NYSE:ANVS) plunges 49.3% premarket after announcing new clinical efficacy and biomarker data of its drug ANVS401 at the 2021 Alzheimer's Association International Conference (AAIC).
ANVS401 reverses the toxic cascade, starting with lowering the levels of neurotoxic proteins, improving the health of the axon, reduced inflammation and improving cognition and motor function.
In addition, data from 14 Alzheimer's disease (AD) patients show that from baseline to 25 days in the Posiphen, dubbed ANVS401-treated group, ADAS-Cog11 improved by 4.4 points, a statistically significant improvement of 30% (p<0.05).
Posiphen-treated group compared to placebo at baseline and 25 days showed an improvement of 3.3 points, or 22% (p=0.13).
Posiphen-treated group showed trends of improvement in all four ADAS-Cog tests compared to placebo.
In Parkinson's disease (PD) patients, Posiphen-treated group showed trends of improvement in all four parts of UPDRS test compared to placebo.
In WAIS coding test, ANVS401-treated AD patients show a 6.6 point and PD patients a 6.1 point improvement in coding.
However, changes in MMSE scores are not statistically significant compared to placebo.
50% and 30% of AD and PD patients (N=10) encountered adverse events. Most AEs were due to the spinal fluid extraction that resulted in headaches and back aches.
Feuerstein Strikes Again
l=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=RSI&Indicator2=BBW&Indicator3=AccDist&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
It's Adam Feuerstein & Stat News out with a short FUD report.
I got out of this one around 100, but happy to be able to get back in when this settles down, which will probably take a while to recover.
I like the MOA of this one & Maria is awesome.
There was no chance of hitting stat sig with 14 patients. The FUD guys love to hammer on that one.
This could be an over reaction to Anavex news, that anavex prevents ad..
I think Annovis and Anavex will be a mighty fine combo someday..
20% of people will not respond to Anavex...
How many millions will need more than restoration to recover in three years?
Millions upon millions..
Liked it at $7
Loved it at $30
Excited about $50
Saw it going to $100
Beautiful things still to come..
Clinical data released this fall should be very exciting..
We have to find a way to speed up clinical trials and access to drugs that may stop death sentence diseases.. other than cancer..
Is this concern over
Not statistically significant?
The group w
Of patients was small.. very small..
Concern over bad reactions?
They were taking spinal samples from old people.. ouch..perhaps They won’t need to do that in later trials.
Great run.. they have lots of cash..
I am Still anticipating great news from addional studies with more participants this fall.
I like the leadership
And the drug
Keep sticking with it
It did for a split second...maybe this week we will break and sustain $100
Anyone think they'll do a forward split at some point (might be a good thing?)
What a after hours...I guess orphan drug designation could come between now and next month and P3 study could begin relatively soon
Moving on up...Glad I held on.
Could happen sooner than I thought
Could challenge its 52 week high by end of Summer.
Nice consolidation after huge move.
ANVS has been sweet. With the right news, these biotechs will run as hard as a meme stock
For new owners of annovis..
Our CEO has sold Companies before
and is well aware of the value of partnerships.
The float is only 4-5 million shares so there is the possibility that a multiple of
That number is SHORT in the market place.
It will be difficult for institutional buyers not to own a piece of such an increddible drug..
New Confirmatory clinical news will be occurring over the next few months..imo
Still well undervalued..imo
Thx for posting
Clay did a good video here. Especially at around the 51 second mark where he does that arrow thing. It is a big red arrow, for a reason. The price over the next several weeks or month and a half will try to close the gap. I do not think it will close it but still, that is so far down there.
Agree I’m not going to lie sold some today but I’m playing with only house money now. I may increase my position but in the short term I’m looking at SLS for their phase 3 data peak on June 3rd.
CEO live tomorrow. There are links to sign up in the press release on their website. Don't know if it will move the stock price, but after the past couple of days, I'll take anything.
Thu, 20 May 2021
BERWYN, PA., May 20, 2021 -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. Maccecchini , Ph.D., will participate in the Alzheimer Disease Panel, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday May 26th, 2021 at 11:00 a.m. ET.
Any news on the next thing that will make this pop !?
Yes very good news!
Few shares..
enough clinical
Money to get through phase 3..
* * $ANVS Video Chart 05-24-2021 * *
Link to Video - click here to watch the technical chart video
It allows for a quicker approval process as the patients should be easier to recruit for phase 3 (inclusion criteria are more defined for Down Syndrom patients. Besides, they are a rather large population).
Annovis will also very probably get Orphan Drug designation.
can somebody elaborate or post info to explain the company's strategy for the capital raise and their targeting of AD in down syndrome.
Price predictions?
Company will have an extra $50M cash later this week.
Hedge funds, University endowment funds, pension plans, and mutual funds and other tutes loading shares.
The OS will increase by 1M. I see the super low trading float still at around 4M or even less. ANVS will move up with ease.
Plus an announcement of big Pharma that may do a joint venture, creating huge upside value!!!!!
The offering will close in 72 hours. > May 26, 2021 > Annovis Bio Priced 1M Share Public Offering @$50/Share
6:42 pm ET May 23, 2021 (Benzinga) Print
Annovis Bio (NYSE: ANVS) today announced the pricing of its underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $50.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock are being offered by the Company.
The offering is expected to close on May 26, 2021, subject to satisfaction of customary closing conditions.
ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering and Maxim Group LLC is acting as co-manager for the offering.
The Company intends to use the net proceeds from the offering primarily for general corporate purposes, including working capital, research and development, capital expenditures and the completion of our planned Phase 3 clinical trial for ANVS401 in AD in persons with Down Syndrome
This is good news correct ?
Seems like we could soar tmw
The offering is only 1 million shares at $50
Offering is out? Isn’t it like 50 for 1 million shares ?
it depends on the offering, it could deep to 40s where I ll be reloading again :)
Price target for Monday ?
I hit the sell on some but have plenty left
Followers
|
45
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
356
|
Created
|
02/04/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |